Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload



Status:Active, not recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:2 - 17
Updated:12/12/2018
Start Date:October 21, 2015
End Date:January 19, 2024

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload

This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment
compliance and change in serum ferritin of a deferasirox granule formulation and a
deferasirox DT formulation in children and adolescents aged ≥ 2 and < 18 years at enrollment
with any transfusion-dependent anemia requiring chelation therapy due to iron overload, to
demonstrate the effect of improved compliance on iron burden.

Randomization will be stratified by age groups (2 to <10 years, 10 to <18 years) and prior
iron chelation therapy (Yes/ No). There will be two study phases which include a 1 year core
phase where patients will be randomized to a 48 week treatment period to either Deferasirox
DT or granules, and an optional extension phase where all patients will receive the granules
up to 5 years. Patients who demonstrated benefit to granules or DT in the core phase, and/or
express the wish to continue in the optional extension phase on granules, will be offered
this possibility until there is local access to the new formulation (granules or FCT) or up
to 5 years, whichever occurs first.


Inclusion Criteria:

- Written informed consent/assent before any study-specific procedures. Consent will be
obtained from parent(s) or legal guardians. Investigators will also obtain assent of
patients according to local guidelines.

- Male and female children and adolescents aged ≥ 2 and < 18 years. [France: Male and
female children and adolescent aged ≥ 2 and < 18 years old, however children aged ≥ 2
and ≤ 6years can be enrolled only when deferoxamine treatment is contraindicated or
inadequate in these patients as per investigator decision. Applicable to core phase
only. Once in the core phase patients can turn 18 years and still be considered
eligible, also for participation in the optional extension phase.

- Any transfusion-dependent anemia associated with iron overload requiring iron
chelation therapy and with a history of transfusion of approximately 20 PRBC units and
a treatment goal to reduce iron burden (300mL PRBC = 1 unit in adults whereas 4 ml/kg
PRBC is considered 1 unit for children).

- Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the
mean value will be used for eligibility criteria).

- Patient has to have participated and completed the 48 weeks core phase treatment as
per protocol (For optional extension phase eligibility only).

Exclusion Criteria:

- Creatinine clearance below the contraindication limit in the locally approved
prescribing information (using Schwartz formula) at screening visit 1 or screening
visit 2.

- Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and or
screening Visit 2

- ALT and/or AST > 3.0 x ULN at screening visit 1 or screening visit 2.

- (Criterion no longer applicable, removed as part of Amendment 1): Prior iron chelation
therapy.

- Liver disease with severity of Child-Pugh class B or C.

- Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg
in a second morning urine sample at screening Visit 1 or screening Visit 2.

- Patients with significant impaired gastrointestinal (GI) function or GI disease that
may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
resection).

Other protocol-defined Inclusion/Exclusion may apply.
We found this trial at
10
sites
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bronx, New York 10467
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Edegem, Antwerpen 2650
?
mi
from
Edegem,
Click here to add this to my saved trials
6701 Fannin Street
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Oakland, California 94609
?
mi
from
Oakland, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials